PATENT 858610-2003

06/18/02 3.2. 49

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s

O 25 2002 E

Tang et al.

January 18, 2002

Serial No

Filed

For

ATENT & THAT

10/052,323

- 0, 002,020

IMMUNIZATION OF A SALMONELLA PAGENTA

APPLICATION OF A SALMONELLA-BASED VECTOR

Art Unit

To Be Determined

Examiner 5

To Be Determined

745 Fifth Avenue New York, NY 10151

EXPRESS MAIL

Mailing Label Number:

EV073692381US

-Date of Deposit:

July 25, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" Service under 37 CFR 1.10 on the date indicated above and is addressed to the Honorable Commissioner of Patents and Trademarks, Washington, DC 20231.

(Typed or printed name of person mailing paper or fee)

lue Tarke maine of person maining paper or fee)

(Signature of person mailing paper or fee)

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

The Examiner's attention is respectfully directed to the documents which are set forth on the accompanying form PTO-1449. Since these documents were forwarded to, or cited by, the Examiner in related applications, U.S. Serial No. 09/402,527, filed October 5, 1999, and U.S. Serial No. 09/563,826, filed May 3, 2000 (now U.S. Patent 6,348,450) and a copy of each of these documents should be in the parent application files, no additional copy is being forwarded with this Information Disclosure Statement.

-1-

PATENT 858610-2003.2

As this Information Disclosure Statement is being filed before the mailing of the first Office Action on the merits, it is believed that no fee is required for entry of this paper. However, the Commissioner is hereby authorized to charge any such fee, or credit any overpayment to Deposit Account 50-0230.

The filing of this Information Disclosure Statement is not an admission that the documents identified herein constitute prior art to the present application.

Applicants respectfully request that the Examiner considers and make of record the documents cited herewith and that a copy of Form PTO-1449 be initialed by the Examiner and returned to the undersigned.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP Attorney for Applicants

Bv:

Thomas J. Kowalski Reg. No. 32,147 (212) 588-0800

Encs. - PTO Form 1449

Sheet 1 of 10

Based on For	m PTO-1449				ATTY. DOCKET NO.		SERIAL NO.	Shee
(3/90)						N3 2		0.000
	LIST O	F REFERENCES CITED BY	APPLICATE	C C C C S S S S S S S S S S S S S S S S	APPLICANT	03.2	10	0/052,323
		(Use several sheets if necess	sary					
			111 25	2003 E	FILDIC D.	Tan	g et al.	
			1 302		FILING DATE		GROUP	
			CATENTE	TRA	January 18,	2002	То Ве	Determined
EXAMINER		Dogun .		U.S. PAT	ENT DOCUMENTS			
INITIAL	-	DOCUMENT NUMBE	R DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT
	AA	5,616,326	04/01/97	Spibey				
	AB	4,797,368	1/10/89	Carter et	al.			
	AC	4,775,630	10/4/88	Tibbetts	et al			
	AD	4,806,350	2/21/89	Gerber				
	AE	4,863,970	9/5/89	Patel et a				
	AF	4,944,942	7/31/90	Brown et	al			
	AG	4,929,442	5/29/90	Powell				
	AH	4,623,541	11/18/86	Elliot et a	l			
	AI	4,674,490	6/23/87	Frankel et	al			
	AJ	4,594,244	6/10/86	Lehner et	al	·		
	AK	4,405,616	9/20/83	Rajadhyak	sha			
	AL	5,679,647	10/21/97	Carson et a	al.			· · · · · · · · · · · · · · · · · · ·
					uthor, Title, Date, Pertinent Pag		<u> </u>	
	AM	Stephenson, J. "De	fective adenoviruses	as novel vacci	nes for the Flaviviridae." Abstra	ct only, Clin Diag. V	irol. 15 July 1998, vol.	10, pgs 187-194
	AN	Saikh et al. "Are D Vol. 16, pgs 1029-1	NA-based vaccines us 038.	seful for prote	ction against secreted bacterial	toxins? Tetanus toxin	test case." Abstract o	nly, Vaccine. May 199
	AO	Antohi et al. "The r International Immun	reactivity pattern of he sology. May 1998, Vo	magglutinin-s l. 10, pgs 663	pecific clonotypes from mice in -668, abstract only.	munized as neonates	or adults with naked I	DNA." Abstract only.
	AP	Fan et al. "Immuniza pages 870-872, see	ation via Hair Follicles entire article.	s by Topical A	application of Naked DNA to No	ormal Skin." Nature	Biotechnology. Septer	mber 1999, vol. 17,
	AQ	Neimiec et al. "Peri Plasmid Formulation	follicular Transgenic I s in vivo." J. of Pharr	Expression of maceutical Sci	Human Interleukin-1 receptor A ences. June 1997, vol. 86, no.	ntagonist Prtoein fol	owing Topical Applica	tion of Novel Liposom
	AR	Scaria et al. "Comple	Plasmid Formulations in vivo." J. of Pharmaceutical Sciences. June 1997, vol. 86, no. 6, pgs 701-708. Scaria et al. "Complementation of a human adenovirus early region 4 deletion mutant in 293 cells using adenovirus-polylysine-DNA complexes. Abstract only", Gene Ther. June 1995, Vol 2, No. 4, pgs 295-298.					
	AS		English Abstract for International Patent No. WO 94/10323					
	AT	English Abstract for						
MINER					DATE CONSIDERED		 	
CAMINER: Interest in c	nitial if referen	ice considered, whether or not not not considered. Include co	citation is in conform	ance with MP	EP 609. Draw line through			
			-, 3. 6.6 tolli widi ili	ear communic	ation to applicant.			

Based on Form	PTO-1449				ATTY. DOCKET NO.		SERIAL NO.	
(3/90)					858610-2002		10,	/052,323
	LIST OF	REFERENCES CITED BY APPI	LICANT	108°	APPLICANT		<u> </u>	
		(Use several sheets if necessary)	0	: 2002	APPLICANT FILING DATE January 18, 2002	Tan	g et al.	
			(JUL 25) (CC-	FILING DATE		GROUP	
			CATENT	RADE	January 18, 2002	2	То Ве	Determined
					ENT DOCUMENTS			
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
-	AU	4,557,934	12/10/85	Cooper				
	AV	5,703,055	12/30/97	Felgner	et al			
	AW	5,693,622	12/2/97	Wolff et	al			
	AX	5,707,812	1/13/98	Horn et	al			
	AY	5,817,637	10/6/98	Weiner	et al.			
	AZ	5,593,972	1/14/97	Weiner	et al.			
	ВА	5,804,566	_9/8/98	–Garson-e	et-al-			
	BB	5,505,945	4/9/96	Gristina	et al.			:
	ВС	5,580,859	12/3/96	Felgner o	et al			
	BD	5,589,466	12/31/96	Felgner e	et al.			
	BE	5,795,972	8/18/98	Kmiec				
	BF	5,731,181	3/24/98	Kmiec				
	BG	5,830,177	11/3/98	Li et al.				
	ВН	5,753,263	5/19/98	Lishko e	t al			
	BI	5,872,005	2/16/99	Wang et	al.			
	ВЈ	5,206,163	4/27/93	Renard e	et al.			
	вк	5,700,680	12/23/97	Newton	et al.			
-	BL	5,707,618	1/13/98	Armenta	no et al.			
	ВМ	5,792,462	8/11/98	Johnston	et al			
-	BN	5,872,005	2/16/99	Wang et	al.			
	ВО	5,998,382	12/7/99	Furth et a	al.			
	BP	5,756,086	5/26/98	Mcclella	nd et al.			
	BQ	5,851,806	12/22/98	Kovesdi	et al.			
	BR	5,700,910	12/23/97	Metzger	et al.			
	BS	5,846,559	12/8/98	Норр				
	ВТ	5,885,808	3/23/99	Spooner	et al.			
EXAMINER					DATE CONSIDERED			
* EXAMINER: citation if not i	Initial if refe n conformance	erence considered, whether or not one and not considered. Include cop	citation is in conform	mance with	MPEP 609. Draw line through nunication to applicant.			

Based on Form PTO-1449 (3/90)

ATTY. DOCKET NO.

SERIAL NO.

8585610-2003.2

10/052,323

LIST OF REFERENCES CITED BY APP (Use several sheets if necessar

APPLICANT

Tang et al.

FILING DATE

GROUP

			CATENTE	January 1	8, 2002	To Be	Determined
EXAMINER		DOCIDATE TO SE		U.S. PATENT DOCUMENTS			
INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIAT
	BU	5,874,279	2/23/99	Cochran et al.			
·	BV	5,718,902	2/17/98	Yilma et al.			
	BW	5,849,719	12/15/98	Carson et al.	•		
	BX	5,872,154	2/16/99	Wilson et al.			-
	BY	5,872,005	2/16/99	Wang et al.			
	BZ	5,736,387	4/7/98	Paul et al.			
	CA	5,494,807	2/27/96	Paoletti et al.			
	СВ	5,882,877	3/16/99	Gregory et al.			
	СС	5,762,939	6/9/98	Smith et al.			
	CD	5,547,932	8/20/96	Curiel et al.			
	CE	5,658,785	8/19/97	Johnson			
	CF	5,665,362	9/9/97	Inglis et al			
	CG	5,698,443	12/16/97	Henderson et al.			
	СН	5,763,270	6/9/98	Eastman et al.			
	CI	5,770,442	6/23/98	Wickham et al.			
	Cl	5,786,211	7/28/98	Johnson	-		
	СК	5,824,538	10/20/98	Branstrom et al.			
	CL	5,830,463	11/3/98	Duke et al.			
	СМ	5,766,599	6/16/98	Paoletti et al.			
	CN	5,780,448	7/14/98	Davis			
	со	5,662,098	9/2/97	Yoshida			
	СР	5,648,096	7/15/97	Gander et al.			
	CQ	5,645,834	7/8/97	Cockrum			
	CR	5,616,329	4/1/97	Newman et al.			
	cs	5 500 444	6/25/96				
	СТ	5 505 6 12	4/9/96	Gristina et al Gristina et al.			

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-1449 (3/90)	
	CITED BY APPLICANT eets if necessary O
	ATENT & THOSE

ATTY. DOCKET NO.

SERIAL NO.

858610-2003.2

10/052,323

APPLICANT

Tang et al.

FILING DATE

GROUP

January 18, 2002

To Be Determined

EXAMINER		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FU DIC DATE
INITIAL					CLAGO	SOBCLASS	FILING DATE IF APPROPRIATE
-	CU	5,891,690	4/6/99	Massie			
	CV	5,882,877	3/16/99	Gregory et al.			
	CW	5,731,172	3/24/98	Saito et al.			
	СХ	5,698,202	12/16/97	Ertl et al.			
	CY	5,585,362	12/17/96	Wilson et al.			
	CZ	5,707,618	1/13/98	Armentano et al.			
	DA	5,880,102	_3/9/99	George-et-al			
	DB	5,703,055	12/30/97	Felgner et al			
	DC	5,700,470	12/23/97	Saito et al.			
	DD	5,753,500	5/19/98	Shenk et al.			
	DE	5,635,380	6/3/97	Naftilan et al.			
	DF	5,580,859	12/3/96	Felgner et al			
	DG	5,830,877	11/3/98	Carson et al.			
	DH	5,589,466	12/31/96	Felgner et al			
	DI	5,679,647	10/21/97	Carson et al			
	DJ	5,591,439	1/7/97	Plotkin et al			
	DK	5,846,559	12/8/98	Норр			
	DL	5,834,256	11/10/98	Finer et al.			
	DM	5,753,263	5/19/98	Lishko et al			
	DN	5,866,383	2/2/99	Moss et al			
	DO	5,830,177	11/3/98	Li et al			
	DP	5,679,647	10/21/97	Carson et al			
	DQ	5,023,252	6/11/91	Hseih			
	DR	5,139,941	8/18/92	Muzyczka et al.			
	DS	5,552,309	9/3/96	March			
	DT	5,635,380	6/3/97	Naftilan et al			

EXAMINER

DATE CONSIDERED

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Sheet 5 of 10

(3/90)				ATTY. DOCKET NO. SERIAL NO.				
(=)					858610-2003.2 10/052,323			
		REFERENCES CITED BY API	PAGANT JC6	ý	APPLICANT			
	•	(Use several sheets if necessary)	, , , , , , , , , , , , , , , , , , ,	نازر		Tang	g et al.	
		(NIL 25 MM	خ طلان	FILING DATE		GROUP	
		\		January 18, 200	2		Determined	
			ATENT 8	U.S. PAT	ENT DOCUMENTS		10 BC	Determined
EXAMINER INITIAL		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
·	DU	5,670,488	9/23/97	Gregory	et al.			
	DV	5,700,470	12/23/97	Saito et	al.			
	DW	5,716,613	2/10/98	Guber et	al.			
	DX	5,739,118	4/14/98	Саттапо	et al.			
	DY	5,753,500	5/19/98	Shenk et	al.			
	DZ	5,780,280	7/14/98	Lebkows	ki et al.			
	EA	5,789,390	8/4/98	Descame	s_et_al			
	EB	5,820,868	10/13/98	Mittal et	al			
	EC	5,824,544	10/20/98	Armentar	no et al.			
	ED	5,830,730	11/3/98	German e	et al			
	EE	5,679,647	10/21/97	Carson et	al			
	EF	5,817,492	10/6/98	Saito et a	1			
	EG	5,705,151	1/6/98	Dow et a				
	EH	6,087,341	7/11/00	Khavari				
-								
								-
								,
XAMINER					DATE CONSIDERED			
EXAMINER: In citation if not in c	nitial if refere onformance	ence considered, whether or not c and not considered. Include copy	itation is in conforma	nce with N	APEP 609. Draw line through ication to applicant.			

Based on Form P (3/90)	Based on Form PTO-1449 (3/90)					ATTY. DOCKET NO.	SERIAL NO.			
(3/90)						858610-2003.2 10/052,323				
	LIST OF	REFERI	ENCES CITED BY APP	WANE JC	60	APPLICANT				
		(Use sev	veral sheets if necessary		10 E		Tan	g et al.		
			('	UNE JCA	KARK (FILING DATE GROUP				
			'		CARE !	January 18, 200	2	То Ве	Determine	ed
				ATEM		ENT DOCUMENTS				
EXAMINER INITIAL		DO	CUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	I	G DATE ROPRIATE
-	EI	3,837	,340	9/24/74	Counter					
	EJ	3,962	:,424	6/8/76	Zygraich	n et al.				
	EK	3,950),512	4/13/76	Emery e	t al.	1			
	EL	3,608	,030	9/21/71	Tint	-	 			
	EM	3,906	,092	9/16/75	Hilleman	n et al.				
	EN	4,738	,846	4/19/88	Rose et a	al				
	EO	4,089	.801	5/16/78	_Schneide	<u>:</u>				
	EP	4,217,	,344	8/12/80	Vanlerbe	erghe et al	†			
	EQ	4,235,	,871	11/25/80		jopoulos et al				
	ER	4,241,	,046	12/23/80	Papahad	jopoulos et al.				
	ES	4,394,	,448	7/19/83 Szoka, Jr.						
				FC	<u> </u>	ATENT DOCUMENTS	<u> </u>			
		DOC	CUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRANS	SLATION
								0000000	YES	NO
	ET	WO 99	9/15683	4/1/99	WIPO				11.5	NO
	EU	WO 99	9/08713	2/25/99	WIPO					
	EV		0/11092	10/4/90	WIPO				 	
-	EW		2/11028	7/9/92	WIPO			-	 	
	EX		3/03641	1/29/98	WIPO					
•					<u> </u>	Author, Title, Date, Pertinent Pages,	Etc.)			
	EY					and Expression via the skin," Huma		metics 1995 Vol 4 nr	12 nn 2270	2205
	EZ					eko foot-hair." Nature, 405 (6787): 6		Hetics, 1999, von 4, no	. 12, pp. 2215	-2283
	FA) "Use of a rapid, e		oculation method to induce papillomas		abbit papillomavirus DN	NA shows that	the E7 gene
	FB		Choate and Khavari, (1	1997) "Direct Cuta	neous Gene	Delivery in a Human Genetic Skin D	Disease" Huma	n Gene Therany 8: 1659	9-1665	
	FC					fer to the Skin," Human Gene Thera			-1003	
	FD					es, vol 60, no. 3, 163-172	3,,			
EXAMINER		I				DATE CONSIDERED				
* EXAMINER: In citation if not in c	nitial if reference	ence con	sidered, whether or not c	itation is in conform	nance with	MPEP 609. Draw line through				

Based	on	Form	PTO-1449
(3/90)			

ATTY. DOCKET NO.

SERIAL NO.

858610-2003.2

10/052,323

LIST OF REFERENCES CITED BY APP (Use several sheets if necessary

APPLICANT

Tang et al.

FILING DATE

GROUP

January 18, 2002

To Be Determined

. 				FOREIGN PATENT DOCUMENTS			
		DOCUMENT NUMBE	R DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	FE	0 638 316 A1	2/15/95	EUROPE			
	FF	298142 A1	1/11/89	EUROPE			
	FG	406778 A1	1/9/91	EUROPE			
	FH	286798 A2	10/19/88	EUROPE			
	FI	0 773 295 A2	5/14/97	EUROPE			
	FJ	WO 00/66179	11/9/00	WIPO			
	FK	WO 95/05853	3/2/95	WIPO			
	FL	-WO-99/15683	-4/1/99	WIPO			
			OTHER PRIOR AR	T (Including Author, Title, Date, Pertinent Page	es. Etc.)		
	FM	Guo, Z. et al.," Eff January 1, 1996 (A	icient and sustained to	ransgene expression in mature rat oligodendroc	ytes in primary cultur	e." J. Neurosci. Res., v	vol. 43, no. 1, 32-41,
	FN			to the skin."(1997) Molecular Medicine Today,			····
	FO	Panchagnula et al.,	"Animal models for t	ransdermal drug delivery." (1997) Meth. Find.	Exp. Clin. Pharmaco	l., 19(5): 335-341	
	FP			me responses to functional determinants of a ce			
	FQ	Tsukui et al., (1996) "Transgenesis by ac	denovirus-mediated gene transfer into mouse zo	na france sureptococc	car antigen," Immunolo	ogy, vol. 87, 55-63.
	FR						
	FS	Huyghe et al., "Pur	Lu et al., "Topical Applications of Viral Vectors for Epidermal Gene Transfer", The Journal of Investigative Dermatology, vol. 108, no. 5, May 1997 Huyghe et al., "Purification of a Type 5 Recombinant Adenovirus Encoding Human p53 by Column Chromatography", Human Gene Therapy, vol. 6, pp. 1403-1416, November 1995				
	FT	Tang et al., "Butyra	te-inducible and tumo	or-restricted gene expression by adenovirus vect	ors" Cancer Gene T	hernny vol 1 1	15.00 .00.
	FU	Remus et al. "Inser		nto an Established Mammalian Genome Con A			

EXAMINER

F۷

FW

FX

FY

DATE CONSIDERED

Liposome-Plasmid DNA Formulations In Vivo", Journal of Pharmaceutical Sciences, vol. 86, no. 6, June 1997 pp. 701-708, June 1997

Ciernik et al., "Puncture-Mediated Gene Transfer to the Skin", Human Gene Therapy, vol. 7, pp. 893-899, May 20, 1996

Brown et al., "Adenoviral Vectors Given Intravenously to Immunocompromised Mice Yield Stable Transduction of the Colonic Epithelium",

Wang et al., "Correction of a Deletion Mutant by Gene Targeting with an Adenovirus Vector", Molecular and Cellular Biology, vol. 13, no. 2, pp. 918-927,

Tsukui et al., "Transgenesis by adenovirus-meditated gene transfer into mouse zona-free eggs", Nature Biotechnology, vol. 14, pp. 982-985, August 1996 Niemic et al., "DNA Perifollicular Transgenic Expression of Human Interleukin-1 Receptor Antagonist Protein following Topical Application of Novel

Gastroenterology, vol. 112, pp. 1586-1594, 1997

February 1993

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-1449

(3/90)

ATTY. DOCKET NO.

SERIAL NO.

858610-2003.2

10/052,323

(Use several sheets if necessary)

(Use several sheets if necessary)

APPLICANT

GROUP

FILING DATE

Tang et al.

January 18, 2002

To Be Determined

		January 18, 2002	10 Be Determined
		OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)	
	GA	Condon et al., "DNA-based immunization by in vivo transfection of dendritic cells", Nature Medicine,	vol. 2, no. 10, pp. 1122-1126, October 1996
	GB	Yang, N.S. et al., "Gene gun and other non-viral approaches for cancer gene therapy" Nat. Med., vol.	1, no. 5, 481-481, May 1995 (Abstract)
	GC	Raz et al., "Intradermal gene immunization: The possible role of DNA uptake in the induction of cellul vol. 91, pp. 9519-9523, September 1994	lar immunity to viruses", Proc. Natl. Acad. Sci. USA,
	GD	Greenhalgh et al., "Epidermis: An Attractive Target Tissue for Gene Therapy", Gene Therapy, vol. 10.	3, no. 5, pp. 63S-69S, November 1994
	GE	Yokoyama et al., "DNA immunization: Effects of vehicle and route of administration on the induction and Medical Microbiology, vol. 14, pp. 221-230, 1996	of protective antiviral immunity", FEMS Immunology
	GF	Hong et al., "Topical Gene Delivery to Murine Skin", The Society for Investigative Dermatology, Inc.	, pp. 370-373, 1999
	GG	Shi et al., "DNA-based non-invasive vaccination onto the skin", Vaccine, vol. 17, pp. 2136-2141, 199	9
	GH	Johnston et al., "The Use of Microparticle Injection to Introduce Genes Into Animal Cells In Vitro and 1993	d In Vivo", Genetic Engineering, vol. 15, pp. 225-234
	GI	Tang et al., "Vaccination onto bare skin", Nature, vol. 388, pp. 729-730, August 1997	
	GJ	Tang et al., "Genetic immunization is a simple method for eliciting an immune response", Nature, vol.	356, pp. 152-154, March 12, 1992
	GK	Lu et al., "Topical Application of Viral Vectors for Epidermal Gene Transfer", The Society for Invest	igative Dermatology, Inc., vol. 108, pp. 803-808, 199
	GL	Yokoyama et al., "DNA immunization: Effects of vehicle and route of administration on the induction and Medical Microbiology, vol. 14, pp. 221-230, 1996	of protective antiviral immunity", FEMS Immunology
	GM	Weiner N., "Targeted follicular delivery of macromolecules via liposomes", International Journal of P	charmaceuticals, vol. 162, pp. 29-38, 1998
	GN	Li et al., "The feasibility of targeted selective gene therapy of the hair follicle." Nature Medicine, vol.	. 1, no. 7, pp. 705-706, 7 July 1995
	GO	Lu et al., "A model for keratinocyte gene therapy: preclinical and therapeutic considerations" Proc. A March 1996	Assoc. Amer. Phys., vol. 108, no. 2, pp. 165-172,
	GP	Sarphie et al., "Bioavailability following transdermal powdered delivery (TPD) of radiolabeled inulin vol. 47, pp. 61-69, 1997	to hairless guinea pigs", Journal of Controlled Releas
	GQ	Todryk et al., "Induction of immune responses to functional determinants of a cell surface streptococc	cal antigen", Immunology, vol. 87, pp. 55-63, 1996
•	GR	Goldman et al., "In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymeters." 462-466	er", Nature Biotechnology, May 1997, vol. 15, pp.
	GS	Lu et al., "Topical Application of Viral Vectors for Epidermal Gene Transfer", The Society for Invest	tigative Dermatology, Inc., pp. 803-808, 1997
	GT	Donnelley et al, "DNA VACCINES", Life Sciences, vol. 60, no. 3, pp. 163-172, 1997	
	GU	Paul et al., "Transdermal immunization with large proteins by means of ultradeformable drug carriers	", Eur. J. Immunol., vol. 25, pp. 3521-3524, 1995
	GV	Sawamura et al. "In Vivo Transfer of a Foreign Gene to Keratinocytes Using the Hemagglutinating V Investigative Dermatology, Inc., pp. 195-199, 1997	'irus of Japan-Liposome Method", The Society for
	GW	Zhdanov et al., "Nonviral methods of gene transfer in gene therapy", Vopr Med Khim, vol. 43, no. 1,	, 1997 Jan. Feb., pp. 3-12 (Abstract)
EXAMINER		DATE CONSIDERED	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-1449 (3/90)

ATTY. DOCKET NO.

SERIAL NO.

858610-2003.2

10/052,323

(Use several sheets if necessary)

APPLICANT

Tang et al.

FILING DATE

GROUP

			January 18, 2002	To Be Determined					
•		OTHER PROJECTION (Including Auth	nor, Title, Date, Pertinent Pages, Etc.)						
	GX	Lee et al., "Control of immune responses by gene immunization	zation", Ann. Med. Vol. 5, pp. 46-0468, Octob	er 1998 (Abstract)					
•	GY	Lee et al., "Induction of an antigen-specific, CD1-restricte 1998 (Abstract)	Lee et al., "Induction of an antigen-specific, CD1-restricted cytotoxic T lymphocyte response In vivo", J. Exp. Med., vol. 187, no. 3, pp. 433-438, Feb 2, 1998 (Abstract)						
	GZ	Corr et al., "Costimulation provided by DNA immunizatio 1997 (Abstract)	on enhances antitumor immunity", J. Immunol.,	vol. 159, no. 10, pp. 4999-5004, November 15,					
	НА	Lee et al., "Inhibition of IgE antibody formation by plasmi vol. 113, nos. 103, pp. 227-230, May-Jul. 1997 (Abstract)		4+ and CD8+ T Cells", Int. Arch Allergy Immuno					
	нв	Corr et al., "Gene vaccination with naked plasmid DNA: r. (Abstract)	mechanism of CTL priming", J. Exp. Med. Vol	. 184, no. 4, pp. 1555-1560, Oct. 1, 1996					
	—нс— — -		y for effective-intradermal-gene immunization"						
	HD	Raz et al., "Preferential induction of a Th1 immune respon Acad. Sci. USA, vol. 93, no. 10, pp. 5141-5145, May 14,		ation by plasmid DNA immunization", Proc. Nat'					
	HE	Raz et al, "Intradermal gene immunization: the possible ro vol. 91, no. 20., pp. 519-523, Sep. 27, 1994 (Abstract)	le of DNA uptake in the induction of cellular ir	rumunity to viruses", Proc. Natl. Acad. Sci. USA,					
	HF	Krawczynski et al., "Effect of immune globulin on the prevention of experimental hepatitis C virus infection", J. Infect. Dis., vol. 173, no. 4, pp. 822-828, April 1996 (Abstract)							
	HG	Watanabe et al., "Induction of antibodies to a kappa V region by gene immunization", J. Immunol., vol. 151, no. 5, pp. 2871-2876, Sept. 1, 1993 (Abstraction of Action 1997).							
	нн	Silverman et al., "Structural characterization of the second major cross-reactive idiotype group of human rheumatoid factors. Association with the VH4 ge family", Arthritis Rheum., vol. 33, no. 9, pp. 1347-1360, Sept. 1990 (Abstract)							
	н	Carson, "Infectious diseases in day-care centers: transmiss 1987, (Abstract)	sion and approaches to prevention", Drug Intell	. Clin. Pharm., vol. 21, no. 9, pp. 694-701, Sept.					
•	нл	Rhodes et al., "Autoantibodies in infectious mononucleosis antigen", J. Exp. Med., vol. 165, no. 4, pp. 1026-1040, Ap		ing region of the Epstein-Barr virus nuclear					
	нк	Fong et al., "The common occurrence of internal image typ rheumatoid factors", Clin. Exp. Immunol., vol. 64, no. 3, p		d with monoclonal and polyclonal human IgM					
	HL	Goni et al., "Sequence similarities and cross-idiotypic spec Immunol., vol. 135, no. 6, pp. 4073-4079, Dec. 1985 (Abs		gM kappa with anti-gamma-globulin activity", J.					
	НМ	Chen et al., "Characterization of human-rheumatoid factors 162, no.2, pp. 487-500, August 1, 1985, (Abstract)	s with seven antiidiotypes induced by synthetic	hypervariable region peptides", J. Exp. Med., vo					
	HN		Chen et al., "Characterization of an epibody. An antiidiotype that reacts with both the idiotype of rheumatoid factors (RF) and the antigen recognized by RF.", J. Exp. Med., vol. 161, no. 2, pp. 323-331, Feb. 1, 1985 (Abstract)						
	НО	Chen et al., "Delineation of a cross-reactive idiotype on hu 1502-1511, May 1, 1984 (Abstract)	uman autoantibodies with antibody against a syr	nthetic peptide", J. Exp. Med., vol. 159, no. 5, pp					
	НР	Chen et al., "Anti-hypervariable region antibody induced by Acad. Sci. USA, vol. 81, no. 6, pp. 1784-1788, March 198		he structural correlates of idiotypes", Proc. Natl.					
XAMINER			DATE CONSIDERED						

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Based on Form PTO-1449 (3/90)

ATTY. DOCKET NO.

SERIAL NO.

858610-2003.2

10/052,323

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessar)

APPLICANT

Tang et al.

FILING DATE

GROUP

		CATEMATA TO AND ENT	January 18, 2002	To Be Determined						
<u> </u>		OTHER PRIOR ART (Including	Author, Title, Date, Pertinent Pages, Etc.)							
	но	HQ Welch et al., "Increased frequency of rheumatoid factor precursor B lymphocytes after immunization of normal adults with tetanuz toxoid", Clin. Exp. Immunol., vol. 51, no. 2, pp. 299-304, Feb. 1983 (Abstract)								
	HR	Krul, "Advances in Gene Therapy: Clear Progress Depages, December 20, 1996 (Abstract)	Krul, "Advances in Gene Therapy: Clear Progress Despite Setbacks", Therapy Markets and Emerging Technologies Spectrum Publications, Issue 112, 47 pages, December 20, 1996 (Abstract)							
	нѕ	Press Release, "Perkin-Elmer and Kimeragen to Deve September 24, 1996	elop Novel Gene Repair Molecules That Treat Gen	etic Diseases", Norwalk, CT and Newtown, PA,						
	НТ	Stephenson, "New Method to Repair Faulty Genes St	tirs Interest in Chimeraplasty Technique", JAMA, v	vol. 282, no. 2, pp. 119-121. January 13, 1999						
	HU	Mann et al. "Gene localization and developmental ex MAP1B."J. Neurosci. Res., vol. 43, no. 1, pp. 32-41,	pression of light chain 3: a common subunit of micr	otubule-associated protein 1A(MAP1A) and						
	HV	Yang et al. "Gene gun and other non-viral approaches		pp. 481-481. May 1995 (Abstract)						
	HW	Scott et al. "Annual Congress of Dermatologic Resea 808, May 1997 (Abstract)	rch '97. Tours, France, April 10-11, 1997. Abstract	s." J. Invest. Dermatol., vol. 108, no. 5, pp. 803-						
	НХ	Citations from BIOLOGICAL ABSTRACTS:BIO, O	ctober 15, 1997							
	НҮ	English Abstract for German Patent No. DE 3937412								
	HZ	English Abstract for International Patent No. WO 94/	10323							
_	IA	English Abstract for Canadian Patent No. 2,234,201	English Abstract for Canadian Patent No. 2,234,201							
	IB	English Abstract for European Patent Appln. No. 97-2	00773295 (US Patent 5,780,448)							
	IC	English Abstract for European Patent Appln. No. 96-2	00711571 (US Patent 5,62,098)							
<u></u>	ID	English Abstract for European Patent Appln. No. 91-0	20406778 (DE Patent 0406778)							
	IE	English Abstract for European Patent Appln. No. 89-0	90304786 (DE Patent 4944942)							
-3	IF	English Abstract for European Patent Appln. No. 89-0	20298142 (DE Patent 0298142)							
<u> </u>	IG	English Abstract for European Patent Appln. No. 88-4	20286798 (DE Patent 0286798)							
	IH	English Abstract for European Patent Appln. No. 88-0	80256190 (US Patent 4,623,544)							
•	II	English Abstract for European Patent Appln. No. 87-1	10213753 (US Patent 4,674,490)							
	IJ	English Abstract for European Patent Appln. No. 84-34	40116472 (US Patent 4,594,244)							
	IK	English Abstract for European Patent No. 05662098 (U	JS Patent 5,662,098)							
	IL	English Abstract for European Patent No. 05648096 (U	JS Patent 5,648,096)							
	IM	English Abstract for European Patent No. 05645834 (U	JS Patent 5,645,834)							
	IN	English Abstract for European Patent No. 05530102 (U								
	IO	English Abstract for European Patent No. 05505945 (U	IS Patent 5,505,945)							
	IP	English Abstract for German Patent No. DE 3937412 (US Patent 3,937,412)							
	IQ	English Abstract for European Patent No. 05616329 (U	S Patent 5,616,329)							
	IR	English Abstract for European Patent Appln. No. 88-08	0256190 (US Patent 4,623,544)							
EXAMINER			DATE CONSIDERED							

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.